Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Forigerimod acetate by Immupharma for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval
Forigerimod acetate is under clinical development by Immupharma and currently in Phase II for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According...